In Q1 2026, Nuo Therapeutics reported continued expansion of Aurix System revenues, supported by a favorable Medicare National Coverage Determination enabling reimbursement. The company’s business model centers on its FDA-cleared autologous platelet rich plasma device addressing difficult chronic wounds, with strategic growth fueled by a private label distribution agreement with Smith+Nephew. Despite a nascent operating history and competitive market dynamics, Nuo leverages clinical differentiation and reimbursement policy to drive adoption in the advanced wound care sector. Key risks include concentrated product exposure, ongoing losses, and dependence on scalable financing.